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Background-—Oxidative stress has been suggested to play a key role in the development of cardiovascular disease (CVD). The aim
of our study was to investigate the associations of serum peroxiredoxin 4 (Prx4), a hydrogen peroxide–degrading peroxidase, with
incident CVD and all-cause mortality. We subsequently examined the incremental value of Prx4 for the risk prediction of CVD
compared with the Framingham risk score (FRS).
Methods and Results-—We performed Cox regression analyses in 8141 participants without history of CVD (aged 28 to 75 years;
women 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, The Netherlands.
Serum Prx4 was measured by an immunoluminometric assay in baseline samples. Main outcomes were: (1) incident CVD events or
CVD mortality and (2) all-cause mortality during a median follow-up of 10.5 years. In total, 708 participants (7.8%) developed CVD
events or CVD mortality, and 517 participants (6.3%) died. Baseline serum Prx4 levels were signiﬁcantly higher in participants with
incident CVD events or CVD mortality and in those who died than in participants who remained free of outcomes (both P<0.001). In
multivariable models with adjustment for Framingham risk factors, hazard ratios were 1.16 (95% CI 1.06 to 1.27, P<0.001) for
incident CVD events or CVD mortality and 1.17 (95% CI 1.06 to 1.29, P=0.003) for all-cause mortality per doubling of Prx4 levels.
After the addition of Prx4 to the FRS, the net reclassiﬁcation improvement was 2.7% (P=0.01) using 10-year risk categories of CVD.
Conclusions-—Elevated serum Prx4 levels are associated with a signiﬁcantly higher risk of incident CVD events or CVD mortality
and all-cause mortality after adjustment for clinical risk factors. The addition of Prx4 to the FRS marginally improved risk prediction
of future CVD. (J Am Heart Assoc. 2012;1:e002956 doi: 10.1161/JAHA.112.002956)
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E
xperimental and clinical studies suggest that oxidative
stress plays a key role in the pathogenesis of cardio-
vascular disease (CVD).
1–4 Oxidative stress status is usually
deﬁned as overproduction of reactive oxygen/nitrogen spe-
cies in imbalance with endogenous antioxidant defenses,
which in turn result in increased oxidative damage.
5 Several
biomarkers, including target oxidation products and antioxi-
dants, have been proposed for assessment of the level of
oxidative stress, but clinical data examining association
between markers and CVD independent of common risk
factors are limited.
5–7
Recently, peroxiredoxin 4 (Prx4), which is a secretable and
stable isoform of the Prx family of antioxidant peroxidases,
8
has been found in the circulation of humans. Prx4 can be
precisely measured by a validated immunoassay.
9 Previous
evidence has shown abundant cellular antioxidant activity of
Prx4 and other Prx isoforms in all mammals protecting against
oxidative stress.
10–13 So far, a limited number of small-scale
studies have evaluated the association of the serum Prx4 with
clinical data.
9,14 In these studies, serum level of Prx4 was
increased in septic patients compared with that of healthy
individuals and was positively associated with well-established
inﬂammatory markers like procalcitonin, C-reactive protein
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9,14 Recently, a study in patients
presenting to emergency departments showed the incremen-
tal prognostic value of Prxr4 to predict 30-day survival beyond
usual risk predictors.
15
We aimed to investigate whether serum Prx4 is a predictor
of CVD and all-cause mortality. For this study, we used data of
a large-scale observational cohort of the general population
and examined the association of Prx4 with incident CVD
events or CVD mortality, and all-cause mortality. Because a
major clinical application of a biomarker lies within risk
stratiﬁcation and guided preventive strategies,
16–19 we also
evaluated the incremental predictive value of Prx4 above the
Framingham risk score for the 10-year risk of CVD.
Methods
Study Population and Design
The study population was obtained from the Prevention of
Renal and Vascular End-stage Disease (PREVEND) study, a
Dutch cohort drawn from the general population (age range,
28 to 75 years) of the city of Groningen, the Netherlands,
between 1997 and 1998. We have reported details of the
study design and recruitment of participants elsewhere.
20,21
Brieﬂy, 40 856 individuals (47.8%) completed a questionnaire
on demographics, history of cardiovascular and metabolic
outcomes, medication use and pregnancy before their ﬁrst
visit, and collecting an early-morning urine sample in a vial to
measure urinary albumin concentration. Those who were
unable or unwilling to participate, individuals using insulin, and
pregnant women were excluded. The baseline PREVEND
participants were recruited from a total of 6000 individuals
with a urinary albumin concentration ≥10 mg/L and a random
control sample of individuals with a urinary albumin concen-
tration <10 mg/L (n=2592).
In the baseline cohort, serum Prx4 assay was missing for
370 participants, leaving 8222 for the baseline cross-
sectional analyses. The PREVEND study was approved by
the local medical ethics committee at the University Medical
Center Groningen and conformed to the principles outlined in
the Declaration of Helsinki. All participants gave written
informed consent.
Clinical and Biomarker Measurements
In the baseline screening, study participants underwent 2
outpatient visits to assess demographics, anthropometric
measurements, cardiovascular and metabolic risk factors,
health behaviors, and medical family history and to collect two
24-hour urine samples on 2 consecutive days. Furthermore,
information on medication use was substantiated with use of
pharmacy-based data from all community pharmacies in the
city of Groningen.
22 Smoking and alcohol use were based on
self-reports.
Hypertension was deﬁned on the basis of self-report of
diagnosis by a physician, measured hypertension (≥140/
90 mm Hg systolic/diastolic blood pressure), or the use of
blood pressure–lowering agents. Prevalent cases of type 2
diabetes were ascertained if 1 or more of the following criteria
were met: (1) a fasting plasma glucose ≥7.0 mmol/L
(126 mg/dL) or a random sample plasma glucose of
11.1 mmol/L (200 mg/dL), or (2) self-report of diagnosis by
a physician, or (3) use of glucose-lowering agents according to
a central pharmacy registration.
23 Prevalent CVD was deﬁned
on the basis of self-reported physician diagnosis of cardiac,
cerebral, and peripheral events by a physician. Kidney disease
wasdeﬁnedonthebasisofahistoryofkidneydiseaserequiring
dialysis or estimated glomerular ﬁltration rate (eGFR) <60 mL/
min per 1.73 m
2. We used the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation to calculate
eGFR.
24
In all participants, blood sample measurements for
biomarkers were taken after an overnight fast. Serum Prx4
level was measured retrospectively in analogously stored
baseline serum samples by a novel immunoluminometric
assay, which was described previously.
9 The functional assay
sensitivity (interassay coefﬁcient of variation <20%) was
0.51 U/L. The intraassay coefﬁcient of variation was <8%
throughout the range of Prx4 levels.
9,14 Insulin was measured
with an AxSym autoanalyzer (Abbott Diagnostics, Amstelveen,
the Netherlands). Details on assays for total cholesterol, high-
desnity lipoprotein (HDL) cholesterol, triglycerides, hs-CRP,
and procalcitonin have been described previously.
25 These
baseline assays were performed in EDTA–plasma aliquots that
had been stored frozen at 80°C without previous thawing
and refreezing. Twenty-four-hour urinary albumin excretion
(UAE)—given as the mean of the two 24-hour urine excre-
tions—was measured by nephelometry with a threshold of
2.3 mg/L and intra- and interassay coefﬁcients of variation
<2.2% and <2.6%, respectively (Dade Behring Diagnostic,
Marburg, Germany). All technicians were blinded to the
participants’ characteristics.
Deﬁnition of Outcomes
In prospective data, we ascertained the main outcomes as
follows: (1) incident CVD events, (2) incident CVD events or
CVD mortality, and (3) all-cause mortality (up to January 1,
2009). Information (on hospitalization) for incident CVD
events was obtained from PRISMANT, the Dutch national
registry of hospital discharge diagnoses. The validity of this
database has been shown to be good, with 84% of primary
diagnoses and 87% of secondary diagnoses matching the
diagnoses recorded in patients’ charts.
26 Data were coded
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Haccording to the International Classiﬁcation of Diseases (ICD),
9th revision, and the classiﬁcation of interventions. The
incident CVD events were classiﬁed as acute myocardial
infarction (ICD code 410), acute and subacute ischemic heart
disease (ICD 411), and occlusion or stenosis of the precere-
bral (ICD 433) or cerebral arteries (ICD 434), and the
procedures including coronary artery bypass grafting or
percutaneous transluminal coronary angioplasty and other
vascular interventions, namely, percutaneous transluminal
angioplasty or bypass grafting of aorta or peripheral vessels.
Data on mortality were obtained through the municipal
registration. Cause of mortality was ascertained by linking the
number of the mortality certiﬁcate to the primary cause of
mortality as coded by the Dutch Central Bureau of Statistics.
Survival time was deﬁned as the period from baseline to the
date of ﬁrst incident CVD event, CVD mortality, date of death,
or January 1, 2009. In the case when a person had moved to
an unknown destination, the date on which the person was
removed from the municipal registry was used as the censor
date.
27
Statistical Analyses
Data are shown as mean±standard deviation (SD) or median
(quartiles 1 and 3 [Q1, Q3]) for continuous variables, which
were compared by 1-way analysis of variance or the Kruskal–
Wallis test as appropriate. Frequency was used for categorical
variables, which were compared by v
2 test across tertiles of
Prx4. We calculated Spearman correlation coefﬁcients of Prx4
with age, systolic blood pressure, body mass index (BMI),
waist circumference, glucose, total cholesterol, HDL choles-
terol, triglycerides, hs-CRP, procalcitonin, and 24-hour UAE.
We used backward-elimination regression models to examine
which of the clinical variables were independently associated
with Prx4 as a dependent variable. The distribution of Prx4
was highly skewed. To normalize the distribution, we
performed logarithmic transformation of the values of Prx4
before analyses. We used the logarithm base 2 (log2) to allow
for interpretation of results per doubling of Prx4. Interpreta-
tion of results expressed per doubling of Prx4 seems more
meaningful than interpretation per factor 10 change or per
factor e change, which would have been the case if
transformation according to base 10 or transformation
according to the natural logarithm, respectively, would have
been applied. We used Cox proportional hazards regression in
crude and multivariable-adjusted models to examine the
associations of Prx4 with incident CVD and all-cause mortal-
ity. We adjusted for age and sex in model 1. In model 2, we
adjusted for Framingham risk factors including age, sex,
smoking, systolic blood pressure, use of antihypertensive
therapy, diabetes at baseline, total cholesterol, and HDL
cholesterol.
28 We tested the assumptions of proportional
hazards for Cox regression models by Shoenfeld’s global
tests. Finally, in stepwise adjustments, we included alcohol
use, triglycerides, high-sensitivity CRP (hs-CRP), and 24-hour
UAE in model 2.
To assess incremental value of Prx4 for the risk prediction
of CVD, we examined improvement of the prediction of CVD
compared with the Framingham risk score. To do so, we
calculated 10-year general CVD risk on the basis of the
Framingham Risk Score
28 and on the basis of a model with
the Framingham Risk Score and log2 Prx4. Subsequently
the models were compared in terms of the following
measures, taking into account the time-to-event nature of
the data
18,19,29,30: (1) Harrell’s C-statistic for the Cox
proportional hazards regression to quantify the discrimination
performance of the models (ability to distinguish between
individuals with and without outcome); (2) net reclassiﬁcation
improvement (NRI) to examine if individuals with and without
outcome were correctly reclassiﬁed (using the threshold
values <6%, 6% to 20%, and ≥20% for categories of low-,
medium-, and high risk, respectively
28,31); and (3) integrated
discrimination improvement (IDI), a continuous measure of
reclassiﬁcation.
Of the baseline sample of 8592 participants, 451 had a
history of CVD. To do the prospective analyses, we ﬁrst
excluded these prevalent cases of CVD, leaving 8141
participants. For most baseline variables, fewer than 1% were
missing; however, this was up to 8% for self-reported
variables. We performed a single imputation with predictive
mean matching for missing data. This method can be used for
skewed data with <10% missingness, because it produces
less biased estimates for a nonlinear model and imputations
are in the metric of the observed data.
32,33
Moreover, a weighted method was performed to compen-
sate the baseline enrichment for the PREVEND participants
with UAC ≥10 mg/L. Given the frequency of individuals with
UAC ≥10 mg/L (24.4%) in our general population,
20,21,27 we
calculated the weight by sampling fractions. Those with UAC
≥10 mg/L had a weight=0.35, and those with UAC <10 mg/L
had a weight=2.51.
Subsequently, we performed secondary analyses to take
into account residual confounding. To do this, we incorpo-
rated other covariates that might be confounding of the
association between Prx4 and the risk of incident CVD in
combination with the Framingham risk factors (model 2).
First, we further adjusted for BMI or waist circumference in
separate models. Second, we adjusted for family history of
CVD and examined the effects of kidney disease on this
association. Third, we calculated metabolic syndrome, which
was deﬁned according to the National Cholesterol Education
Program’s Adult Treatment Panel III report criteria.
25 And
then we adjusted for metabolic syndrome or insulin in
combination with variables in model 2. Next, we examined
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or CVD mortality including myocardial infarction, cerebro-
vascular disease, and cardiovascular mortality. In addition,
we performed another analysis that included those who had
a history of CVD. In total population, we further adjusted
history of CVD in combination with the variables in model 2.
And then we performed a similar analysis in participants
with a history of CVD. We used Cox proportional hazards
regression with fractional polynomials to search for the best-
ﬁtting functional form of Prx4 in the model for incident CVD
(model 2).
Given the number of each event, we had 80% power at a
0.05 signiﬁcance level to detect a hazard ratio=1.29 for
myocardial infarction, 1.25 for cerebrovascular disease, and
1.23 for CVD mortality. All statistical analyses were carried
out using IBM SPSS 19.0 and R version 2.10.1 (Vienna,
Austria; http://75cran.r-project.org/).
Results
Baseline Characteristics
Baseline clinical characteristics of the total population and
corresponding tertiles of serum Prx4 are summarized in
Table 1. Median (Q1, Q3) Prx4 levels were 0.71 (0.45 to
1.16) U/L in men and 0.66 (0.42 to 1.08) U/L in women
(P<0.001). Across tertiles of Prx4, those who had higher Prx4
levels were older, more obese, less frequent alcohol drinkers,
and more likely to have a history of CVD, hypertension, and
prevalent diabetes.
Table 1. Baseline Characteristics of Study Participants for Total Population’s Corresponding Tertiles of Serum Peroxiredoxin 4*
Characteristic Total Tertiles
†
n 8222 2730 2671 2821
Peroxiredoxin 4, U/L 0.69 (0.44 to 1.12) 0.37 (0.37 to 0.44) 0.68 (0.59 to 0.78) 1.38 (1.10 to 1.97)
Age, year 49.2±12.7 47.1±11.9 48.7±12.4 51.8±13.2
Male sex, n (%) 4107 (50.0) 1276 (46.7) 1325 (49.6) 1506 (53.4)
History of CVD, n (%) 431 (5.4) 80 (3.0) 116 (4.5) 235 (8.7)
Family history of CVD, n (%) 3817 (50.2) 1292 (50.7) 1249 (50.3) 1276 (49.7)
Current smoker, n (%) 2787 (34.0) 1071 (39.4) 897 (33.7) 819 (29.1)
Ex-smoker, n (%) 2984 (36.4) 886 (32.6) 954 (35.9) 1144 (40.7)
Alcohol drinker, n (%) 6110 (74.7) 2121 (78.0) 2021 (75.9) 1968 (70.2)
BMI, kg/m
2 26.1±4.2 25.3±3.8 26.1±4.2 26.8±4.5
Waist circumference, cm 88.5±13.0 86.0±12.1 88.3±12.8 91.2±13.8
Systolic blood pressure, mm Hg 124.5±19.6 121.0±17.5 124.0±19.3 128.3±21.1
Diastolic blood pressure, mm Hg 71.8±9.7 70.3±9.0 71.8±9.8 73.3±10.2
Antihypertensive therapy, n (%) 1282 (15.6) 294 (10.8) 396 (14.8) 592 (21.0)
Prevalent diabetes, n (%) 315 (4.0) 49 (1.9) 96 (3.7) 170 (6.2)
Fasting glucose, mg/dL 4.9±1.2 4.7±0.9 4.9±1.2 5.0±1.4
Total cholesterol, mmol/L 5.64±1.13 5.63±1.09 5.60±1.12 5.70±1.16
HDL cholesterol, mmol/L 1.32±0.40 1.37±0.40 1.32±0.39 1.27±0.40
Triglyceride, mmol/L 1.16 (0.85 to 1.68) 1.11 (0.81 to 1.56) 1.13 (0.83 to 0.164) 1.26 (0.90 to 1.88)
Metabolic syndrome, n (%) 1378 (18.2) 314 (12.3) 444 (17.9) 629 (24.5)
Fasting insulin, mmol/L 8.0 (5.6 to 12.1) 7.2 (5.2 to 10.2) 8.0 (5.5 to 11.9) 9.1 (6.2 to 14.3)
hs-CRP, mg/L 1.27 (0.55 to 2.96) 0.93 (0.42 to 2.08) 1.22 (0.55 to 2.82) 1.85 (0.79 to 4.27)
Procalcitonin, ng/mL 0.016 (0.013 to 0.20) 0.015 (0.013 to 0.018) 0.016 (0.013 to 0.019) 0.017 (0.014 to 0.021)
UAE, mg/24 h 9.45 (6.33 to 17.8) 8.76 (6.16 to 14.36) 9.11 (6.21 to 16.23) 10.87 (6.64 to 24.99)
CVD indicates cardiovascular disease; BMI, body mass index, which is the weight in kilograms divided by the square of the height in meters; HDL, high-density lipoprotein; hs-CRP, high-
sensitivity C-reactive protein; and UAE, urine albumin excretion. Metabolic syndrome was deﬁned according to the National Cholesterol Education Program’s Adult Treatment Panel III
report criteria.
*Data are mean (±SD) and median (quartiles 1 and 3) for continuous variables and percentage for categorical variables in complete baseline data set. For clinical variables, up to 1.2% was
missing. For self-reported data, 0.4% to 7.8% was missing. For biomarkers, 0.2% to 6.4% was missing.
†P<0.001 for the comparison among all peroxiredoxin 4 tertile groups, except for total cholesterol (P=0.005) and family history of CVD (P=0.77).
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circumference, systolic blood pressure, glucose, triglycerides,
insulin, 24-hour UAE, and inﬂammatory biomarkers of hs-CRP
and procalcitonin and were inversely correlated with HDL
cholesterol (P<0.001 for all correlations) (Table 2). In the
backward-elimination regression model, log2 Prx4 was posi-
tively associated with age (b=0.006, P<0.001), history of CVD
(b=0.203, P=0.001), triglycerides (b=0.048, P<0.001), log2
hs-CRP (b=0.102, P<0.001), log2 UAE (b=0.050, P<0.001),
and log2 insulin (b=0.102, P<0.001) and was inversely
associated with female sex (b=0.059, P=0.03), alcohol
use (b=0.083, P<0.001), and total cholesterol (b=0.060,
P<0.001) (Table 3).
Incident CVD and All-Cause Mortality
During median (Q1, Q3) follow-up of 10.5 (9.9 to 10.8) years,
663 participants (8.1%) developed incident CVD events, 708
participants (8.7%) developed incident CVD events or CVD
mortality, and 517 participants (6.3%) died (of whom 135 died
of cardiovascular causes). Median (Q1, Q3) Prx4 levels were
0.88 (0.54 to 1.45) U/L and 0.85 (0.53 to 1.46) U/L in
participants who developed incident CVD events or CVD
Table 2. Spearman Correlation Coefﬁcients of Serum
Peroxiredoxin 4 With Baseline Variables*
Variable Correlation Coefﬁcient (95% CI)
Age 0.154 (0.131 to 0.177)
Systolic blood pressure 0.148 (0.117 to 0.164)
Body mass index 0.150 (0.128 to 0.170)
Waist circumference 0.167 (0.146 to 0.187)
Glucose 0.114 (0.088 to 0.135)
Total cholesterol 0.020 (0.000 to 0.044)
HDL cholesterol 0.118 (0.141 to 0.098)
Triglycerides 0.105 (0.080 to 0.133)
Insulin 0.181 (0.160 to 0.201)
hs-CRP 0.229 (0.205 to 0.249)
Procalcitonin 0.129 (0.107 to 0.153)
UAE 0.126 (0.104 to 0.150)
HDL indicates high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; and
UAE, urine albumin excretion.
*Data were available for 7638 to 8222 participants. We used the bootstrapping method
to calculate 95% conﬁdence intervals (CIs). P values were <0.001 for all correlations,
except for total cholesterol (P=0.096).
Table 3. Association of Baseline Variables With Serum Peroxiredoxin 4 as Dependent Variable*
Unadjusted Age- and Sex Adjusted Multivariable Adjusted
†
b Coefﬁcients (SE) P b Coefﬁcients (SE) P b Coefﬁcients (SE) P
Age, per increase of 1 year 0.011 (0.001) <0.001 0.011 (0.001) <0.001 0.006 (0.001) <0.001
Sex, female vs male 0.081 (0.022) <0.001 0.061 (0.022) 0.005 0.059 (0.027) 0.03
History of CVD, yes vs no 0.406 (0.049) <0.001 0.261 (0.050) <0.001 0.203 (0.052) 0.001
Smoking, yes vs no 0.032 (0.013) 0.02 0.006 (0.013) 0.67 ——
Alcohol use, yes vs no 0.172 (0.025) <0.001 0.158 (0.025) <0.001 0.083 (0.026) 0.001
BMI, per increase of 1 kg/m
2 0.029 (0.003) <0.001 0.021 (0.003) <0.001 ——
Waist circumference, per increase of 1 cm 0.010 (0.001) <0.001 0.008 (0.001) <0.001 0.002 (0.001) 0.071
Systolic blood pressure, per increase of 1 mm Hg 0.007 (0.001) <0.001 0.004 (0.001) <0.001 0.001 (0.001) 0.074
Antihypertensive therapy, yes vs no 0.309 (0.030) <0.001 0.194 (0.023) <0.001 0.059 (0.035) 0.10
Prevalent diabetes, yes vs no 0.422 (0.057) <0.001 0.291 (0.058) <0.001 ——
Total cholesterol, per increase of 1 mmol/L 0.027 (0.035) 0.006 0.015 (0.010) 0.13 0.060 (0.011) <0.001
HDL cholesterol, per increase of 1 mmol/L 0.227 (0.027) <0.001 0.204 (0.029) <0.001 ——
Triglycerides, per increase of 1 mmol/L 0.104 (0.011) <0.001 0.081 (0.011) <0.001 0.048 (0.013) <0.001
Insulin, per increase of log2 unit 0.198 (0.013) <0.001 0.171 (0.013) <0.001 0.102 (0.017) <0.001
hs-CRP, per increase of log2 unit 0.220 (0.023) <0.001 0.114 (0.007) <0.001 0.102 (0.008) <0.001
Procalcitonin, per increase of log2 unit 0.127 (0.007) <0.001 0.152 (0.024) <0.001 0.049 (0.026) 0.10
24-hour UAE, per increase of log2 unit 0.101 (0.009) <0.001 0.075 (0.009) <0.001 0.050 (0.010) <0.001
BMI indicates body mass index, which is the weight in kilograms divided by the square of the height in meters; SE, standard error; HDL, high-density lipoprotein; hs-CRP, high-sensitivity
C-reactive protein; UAE, urine albumin excretion.
*Base-two logarithmically transformed serum level of peroxiredoxin 4 was the dependent variable.
†Backward selection was used when dropping nonsigniﬁcant variables (probability for removal was 0.10 by F test).
DOI: 10.1161/JAHA.112.002956 Journal of the American Heart Association 5
Peroxiredoxin 4 and Cardiovascular Disease Abbasi et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
Hmortality and all-cause mortality, respectively. In Figure 1, the
cumulative survival to incident CVD events and to incident
CVD events or CVD mortality is shown based on tertile
groups. The crude cumulative incidence rates (per 1000
person-years) and hazard ratios (HRs) with 95% conﬁdence
intervals (95% CIs) in crude and multivariable-adjusted models
for the risk of developing incident CVD events, incident CVD
events or CVD mortality, and all-cause mortality are shown in
Table 3. Age- and sex-adjusted HRs (95% CIs) ranged from
1.32 (1.07 to 1.63) for incident CVD events to 1.40 (1.08 to
1.79) for all-cause mortality when comparing the highest
tertile with the ﬁrst tertile of Prx4 (P for trend <0.001). In a
model adjusted for the Framingham risk factors, Prx4 was
signiﬁcantly associated with an increased risk of incident CVD
and all-cause mortality. The proportional hazards assumptions
were met for all models.
In further models, stepwise adjustment for alcohol use,
triglycerides, hs-CRP, and 24-hour UAE minimally attenuated
the associations of Prx4 with incident CVD events or CVD
mortality. This was comparable to calculation of HR per
doubling of Prx4 level for each outcome. We observed a 15%
increased risk of incident CVD events independent of the
Framingham risk factors per doubling of Prx4 level (HR 1.15,
95% CI 1.05 to 1.26). This was a 16% and a 17% increase for
incident CVD events or CVD mortality (HR 1.16, 95% CI 1.06
to 1.27) and all-cause mortality (HR 1.17, 95% CI 1.06 to
1.29), respectively (Table 4). In subsequent analyses, the
associations of Prx4 with the risk of either incident CVD or all-
cause mortality were similar for men and women (data not
shown).
To assess the incremental predictive value of Prx4 for the
risk of CVD, we added Prx4 to the Framingham Risk Score as
a continuous variable.
28 In our data set, the Framingham risk
score had a C-statistic (95% CI) of 0.80 (0.78 to 0.82) for the
10-year risk of CVD. The addition of Prx4 modestly improved
the C-statistic to 0.81 (0.79 to 0.82, P=0.02) and led to IDI of
0.003 (P<0.001) and NRI of 2.7% (95% CI 0.7% to 4.7%;
P=0.01) (Table 5). In patients without incident CVD events or
CVD mortality, use of Prx4 reclassiﬁed 1% and 4% of
participants in lower- and higher-risk categories (<6% and
>20%), respectively. In patients with incident CVD events or
CVD mortality, use of Prx4 reclassiﬁed 2% and 4% of
participants in lower- and higher-risk categories, respectively.
Secondary Analyses
Tables 6 and 7 show the results of secondary analyses.
Separately, adjustment for BMI or waist circumference in
combination with the Framingham risk factors (ie, model 2)
did not materially change the association of Prx4 with risk of
incident CVD events or CVD mortality. Moreover, our results
adjusted for both kidney disease and family history of CVD
were similar to those of model 2. In addition, further
adjustment for metabolic syndrome or insulin in model 2
Figure 1. The cumulative probability of incident CVD events (A) and incident CVD events or CVD mortality (B) is shown by tertiles of Prx4. Data are
shown for 8141 participants without CVD at baseline. CVD events were deﬁned as a composite of nonfatal incident cardiac, cerebral, and peripheral
vascularevents.Overall,thelog-ranktestsweresigniﬁcantforalloutcomesaccordingtothetertilesofserumperoxiredoxin4(P<0.001).CVDindicates
cardiovascular disease.
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Prx4 was associated with the components of incident CVD
events or CVD mortality including myocardial infarction,
cerebrovascular disease, and CVD mortality. After adjustment
for the variables in model 2, HR (95% CI) in the highest tertile
compared with the ﬁrst tertile of Prx4 was 1.03 (0.71 to 1.50),
1.28 (0.85 to 1.93), and 1.22 (0.71 to 2.12) for myocardial
infarction, cerebrovascular disease, and CVD mortality,
respectively.
Inanotheranalysis,weexaminedtheassociationofPrx4with
riskofincidentCVDafteradjustmentforthevariablesinmodel2
andahistoryofCVDinthetotalpopulation.TheadjustedHR(95%
CI)inthehighesttertilecomparedwiththeﬁrsttertileofPrx4was
1.32 (1.11 to 1.59) for incident CVD events or CVD mortality. In
Table 4. Association of Serum Peroxiredoxin 4 With Incident CVD Events, Incident CVD Events or CVD Mortality, and All-Cause
Mortality (n=8141)*
HR (95% CI) or No. of Cases (Incidence Rate) According to Tertiles
of Prx4
HR (95% CI) Per Log2 Unit Increase* P 12 3
Incident CVD events
No. of cases, per 1000 person-years 151 (5.8) 204 (7.8) 308 (12.3)
Unadjusted analysis 1.00 1.19 (0.95 to 1.48) 1.73 (1.40 to 2.13) 1.32 (1.21 to 1.44) <0.001
Model 1 1.00 1.04 (0.84 to 1.30) 1.32 (1.07 to 1.63) 1.21 (1.10 to 1.33) <0.001
Model 2 1.00 1.06 (0.84 to 1.32) 1.26 (1.01 to 1.57) 1.15 (1.05 to 1.26) 0.003
Model 2+alcohol use 1.00 1.06 (0.84 to 1.32) 1.25 (1.01 to 1.55) 1.14 (1.04 to 1.25) 0.004
Model 2+TG 1.00 1.06 (0.85 to 1.33) 1.28 (1.03 to 1.59) 1.16 (1.06 to 1.27) 0.001
Model 2+CRP 1.00 1.05 (0.84 to 1.31) 1.22 (0.98 to 1.52) 1.11 (1.01 to 1.22) 0.02
Model 2+UAE 1.00 1.05 (0.84 to 1.32) 1.25 (1.01 to 1.55) 1.15 (1.05 to 1.25) 0.003
Model 2+alcohol use, TG, CRP, and UAE 1.00 1.06 (0.84 to 1.32) 1.23 (1.00 to 1.53) 1.12 (1.02 to 1.23) 0.02
Incident CVD events or CVD mortality
No. of cases, per 1000 person-years 160 (6.1) 215 (8.2) 333 (13.3)
Unadjusted analysis 1.00 1.17 (0.94 to 1.45) 1.78 (1.46 to 2.19) 1.33 (1.23 to 1.45) <0.001
Model 1 1.00 1.02 (0.82 to 1.27) 1.35 (1.10 to 1.66) 1.22 (1.12 to 1.33) <0.001
Model 2 1.00 1.03 (0.83 to 1.29) 1.29 (1.05 to 1.59) 1.16 (1.06 to 1.27) <0.001
Model 2+alcohol use 1.00 1.03 (0.83 to 1.29) 1.29 (1.04 to 1.58) 1.16 (1.06 to 1.26) 0.001
Model 2+TG 1.00 1.04 (0.84 to 1.30) 1.32 (1.07 to 1.62) 1.18 (1.08 to 1.28) <0.001
Model 2+CRP 1.00 1.03 (0.82 to 1.28) 1.26 (1.02 to 1.56) 1.13 (1.03 to 1.23) 0.01
Model 2+UAE 1.00 1.03 (0.83 to 1.29) 1.29 (1.05 to 1.59) 1.16 (1.06 to 1.27) 0.001
Model 2+alcohol use, TG, CRP, and UAE 1.00 1.03 (0.83 to 1.29) 1.27 (1.03 to 1.57) 1.13 (1.03 to 1.24) 0.008
Incident all-cause mortality
No. of cases, per 1000 person-years 117 (4.4) 160 (5.9) 240 (9.1)
Unadjusted analysis 1.00 1.43 (1.10 to 1.86) 2.00 (1.56 to 2.57) 1.36 (1.23 to 1.50) <0.001
Model 1 1.00 1.25 (0.96 to 1.62) 1.40 (1.08 to 1.79) 1.20 (1.08 to 1.33) <0.001
Model 2 1.00 1.27 (0.98 to 1.66) 1.41 (1.09 to 1.82) 1.17 (1.06 to 1.29) 0.003
Model 2+alcohol use 1.00 1.27 (0.98 to 1.66) 1.41 (1.09 to 1.82) 1.17 (1.06 to 1.30) 0.002
Model 2+TG 1.00 1.26 (0.97 to 1.65) 1.39 (1.07 to 1.79) 1.16 (1.05 to 1.29) 0.004
Model 2+CRP 1.00 1.24 (0.95 to 1.62) 1.26 (0.97 to 1.64) 1.09 (0.98 to 1.21) 0.11
Model 2+UAE 1.00 1.27 (0.98 to 1.66) 1.40 (1.08 to 1.81) 1.15 (1.04 to 1.28) 0.006
Model 2+alcohol use, TG, CRP, and UAE 1.00 1.23 (0.94 to 1.60) 1.24 (0.96 to 1.61) 1.08 (0.97 to 1.20) 0.18
Cardiovascular disease (CVD) events were deﬁned as a composite of incident cardiac, cerebral, and peripheral vascular events. Participants with a history of CVD were excluded. These
associations did not differ by sex. Hazard ratios (HRs) with 95% conﬁdence intervals (CIs) have been adjusted for age and sex in model 1 and for the Framingham risk factors including age,
sex, smoking, systolic blood pressure, use of antihypertensive therapy, diabetes at baseline, total cholesterol, and HDL cholesterol in model 2. TG indicates triglyceride; CRP, C-reactive
protein; and UAE, urine albumin excretion.
*Base-two logarithmically transformed Prx4, CRP, and 24-hour UAE were analyzed as continuous variables. Individuals with prevalent CVD were excluded.
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the variables in model 2 in the highest tertile compared with the
ﬁrst tertile of Prx4 was 1.07 (0.73 to 1.56) for incident CVD
events or CVD mortality (n=181).
Figure 2 depicts the relationship of continuous Prx4 with
incident CVD events or CVD mortality. We plotted for
Framingham risk factor–adjusted (model 2) HRs and their
95% CIs as a function of Prx4. The optimal transformation was
one in which the terms (Prx4)
1/2 and (Prx4)
1/29ln(Prx4) were
incorporated. The solid line demonstrates that after a slight
decrease in risk with levels slightly higher than the lowest
ones that can be detected, the risk associated with increasing
levels of Prx4 steeply increases until a plateau is reached with
high levels of Prx4. Incremental value for risk prediction with
the addition of (Prx4)
1/2 and (Prx4)
1/29ln(Prx4) to the model
rather than log2-linear transformed Prx4 (C-statistic=0.81,
95% CI 0.79-0.82; IDI=0.004, P<0.001; NRI=3.6%, 95% CI
1.5% to 5.7%, P<0.001) was slightly higher, but very similar to
that with log2-linear transformed Prx4.
Discussion
In this study, we demonstrated that serum Prx4, a circulating
biomarker with antioxidant properties, was associated with
the most common risk factors of CVD in a large general
population cohort enriched with individuals with microalbu-
minuria. We found it to have an statistically signiﬁcant positive
association with age, history of CVD, systolic blood pressure,
antihypertensive therapy, triglycerides, hs-CRP, UAE, and
procalcitonin, wherea there was an inverse association with
alcohol use and total cholesterol. Moreover, higher serum
Prx4 levels were associated with signiﬁcantly higher risk of
incident CVD and all-cause mortality. For potential clinical
application, we examined the incremental predictive value of
Prx4 compared with the Framingham risk score. In particular,
Prx4 modestly improved prediction for the 10-year CVD risk
when added to the Framingham risk score in terms of
discriminative ability and net reclassiﬁcation.
Our ﬁndings showing the associations of serum Prx4 level
with cardiovascular risk factors and events support previous
clinical studies suggesting a role of oxidative stress in the
pathogenesis of CVD.
1,2,4,34 In an earlier study, a higher
Table 5. Reclassiﬁcation of Participants for the 10-Year Risk
Prediction of Cardiovascular Disease Corresponding to the
Framingham Risk Score and After Adding Serum
Peroxiredoxin 4*
Framingham Risk
Category
Framingham Risk Score With Prx4
Low
Risk
Intermediate
Risk
High
Risk
Reclassiﬁcation
(%)
In participants without outcome
Low risk 4647 38 0 1.0
Intermediate risk 207 1984 81 13.0
High risk 0 23 494 4.0
In participants with outcome
Low risk 104 2 0 2.0
Intermediate risk 9 299 24 10.0
High risk 0 9 213 4.0
Total sample
Low risk 4751 40 0 1.0
Intermediate risk 216 2283 105 12.0
High risk 0 32 707 4.0
*Corresponding to the Framingham risk score and after adding serum peroxiredoxin 4,
low risk denotes <6%, intermediate risk 6% to 20%, and high risk >20% for the 10-year of
cardiovascular disease. Net reclassiﬁcation index was 2.7 (95% CI 0.7 to 4.7; P=0.01),
and integrated discrimination improvement was 0.0032 (95% CI 0.0014 to 0.0049;
P<0.001).
Table 6. Association of Serum Peroxiredoxin 4 With Incident Cardiovascular Events or CVD Mortality (n=8141)
Model
HR (95% CI) by Tertiles of Peroxiredoxin 4 (U/L)
12 3
Adjusted for model 2 1.00 1.03 (0.83 to 1.29) 1.29 (1.05 to 1.59)
Adjusted for model 2+BMI 1.00 1.03 (0.83 to 1.28) 1.29 (1.05 to 1.59)
Adjusted for model 2+waist circumference 1.00 1.03 (0.83 to 1.28) 1.31 (1.06 to 1.59)
Adjusted for model 2+family history of CVD 1.00 1.04 (0.83 to 1.29) 1.30 (1.06 to 1.60)
Adjusted for sex, age, smoking+metabolic syndrome 1.00 1.03 (0.82 to 1.28) 1.38 (1.12 to 1.76)
Adjusted for model 2+insulin 1.00 1.04 (0.83 to 1.30) 1.31 (1.06 to 1.61)
Adjusted for model 2+kidney disease 1.00 1.03 (0.83 to 1.29) 1.30 (1.05 to 1.60)
Hazard ratios (HRs) with 95% conﬁdence intervals (95% CIs) have been adjusted for model 2, in which the Framingham risk factors age, sex, smoking, systolic blood pressure, use of
antihypertensive therapy, diabetes at baseline, total cholesterol, and HDL cholesterol were included. Kidney disease was deﬁned on the basis of a history of kidney disease requiring
dialysis or estimated glomerular ﬁltration rate (eGFR) below 60 mL/min per 1.73 m
2. We used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to calculate
eGFR. BMI indicates body mass index; CVD, cardiovascular disease; and HDL, high-density lipoprotein.
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in individuals with renovascular hypertension, which was
correlated with endothelium-dependent vasodilatation.
4
Another study showed the independent association of oxidized
low-density lipoprotein with the incidence of metabolic syn-
drome.
2 In line with this, genotypes and serum activity of
paraoxonase 1, an HDL-related antioxidant, has been shown to
beassociatedwithsystemicoxidativestressandcardiovascular
outcomesinhumans.
1Wenowextendaccumulatinginformation
obtainedfromanimalandhumanstudiesonPrx4ofthefamilyof
thiol-dependentantioxidantsinthisera.Ananimalmodeloftype
1diabeteshasindicatedthatPrx4mayhaveapivotalroleinthe
suppressionofapoptosisandtheproliferationofprogenitorcells
toprotectagainstoxidativestress-inducedb-celldysfunction.
12
Inlinewiththis,highergeneexpressionofPrx4hasbeenfoundin
the islets of a high-fat diet model of b-cell dysfunction
35 and
downregulatedexpressionofPrx4inisletsindiabeticmicewith
chronic hyperglycemia.
36 Moreover, recent studies have sug-
gested that Prx4 might be involved in the protection against
celiac disease and cancer in the pancreas and lung with
increased expression and production of Prx4 in the related
human tissues.
12,37,38 Consistently, Prx1, another member of
thePrxfamily,hasalsoshowntobeinvolvedinabroadrangeof
oxidative stress-related outcomes in the cardiovascular sys-
tem.
39,40
Importantly, Prx4 is the only secretable member of the
family in animals and humans.
8,11 Recently, clinical data have
shown that Prx4 levels were increased in sera of septic
patients compared with healthy individuals.
14,15 Consistent
with this, we showed the relation between Prx4 and
inﬂammatory markers and also explored its relation with
measures of adiposity, blood pressure, glycemia index, lipids,
and albuminuria. All these markers are underlying in central
Table 7. Association of Serum Peroxiredoxin 4 With Incident Myocardial Infarction, Cerebrovascular Events, and Cardiovascular
Mortality (n=8141)
Tertiles of Peroxiredoxin 4, U/L
12 3
Incident myocardial infarction
No. of cases, % 51 (5.8) 63 (7.8) 94 (10.1)
Unadjusted HR (95% CI) 1.00 1.04 (0.71 to 1.52) 1.43 (1.00 to 2.06)
Multivariate-adjusted HR (95% CI)* 1.00 0.98 (0.67 to 1.43) 1.06 (0.74 to 1.53)
Incident cerebrovascular disease
No. of cases, % 39 (6.1) 58 (8.2) 88 (13.3)
Unadjusted HR (95% CI) 1.00 1.00 (0.64 to 1.55) 1.73 (1.16 to 2.58)
Multivariate-adjusted HR (95% CI)* 1.00 0.93 (0.60 to 1.45) 1.28 (0.85 to 1.91)
Incident cardiovascular mortality
No. of cases, % 28 (1.0) 44 (5.9) 63 (9.1)
Unadjusted HR (95% CI) 1.00 1.48 (0.84 to 2.59) 2.10 (1.23 to 3.58)
Multivariate-adjusted HR (95% CI)* 1.00 1.35 (0.77 to 2.36) 1.38 (0.80 to 2.36)
*Hazard ratios (HRs) with 95% conﬁdence intervals (95% CIs) have been adjusted for model 2, in which the Framingham risk factors included age, sex, smoking, systolic blood pressure, use
of antihypertensive therapy, diabetes at baseline, total cholesterol, and HDL cholesterol.
Figure 2. The relationship of peroxiredoxin 4 with incident CVD
events or CVD mortality. Data are shown for 8141 participants
without CVD at baseline. The plotted hazard ratio (95% CI) was
adjusted for the Framingham risk factors and centered on the Prx4
median value. The optimal transformation of Prx4 was one in which
the terms (Prx4)
1/2 and (Prx4)
1/29ln(Prx4) were incorporated. CVD
indicates cardiovascular disease.
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27,41 Other
recent data from patients who presented to emergency
departments showed that serum Prx4 level was increased in
nonsurvivors and that there was improved prognostic infor-
mation for survival at 30 days when it was added to a clinical
risk score.
15 One main explanation for these ﬁndings may be
that concomitant production and secretion of Prx4 can be
augmented to protect against the increased rate of oxidative
stress in relation to adverse cardiovascular and metabolic
conditions.
42 Interestingly, in secondary analyses with frac-
tional polynomials, we found support for the notion that very
low levels of Prx4 compared with somewhat higher levels are
associated with a slightly increased risk. Possibly this makes
up a subgroup of subjects with constitutively low levels of
Prx4, which predisposes to CVD. The high risk with more
elevated levels of Prx4 is consistent with a compensatory
increase in Prx4 in response to existing oxidative stress. At
the cellular level, Prx4 may promote antioxidant activity via
several pathways, such as nuclear factor kB,
43 p53,
44
thromboxane A2 receptor,
45 and NF-E2-related factor 2
(Nrf2).
46 Despite equivocal ﬁndings of supplementing antiox-
idant vitamins to prevent cardiovascular and metabolic
diseases,
1,47 a recent trial
48 showed an effective intervention
of a speciﬁc antioxidant, that is, an Nrf2 antagonist that is
related to Prx4 pathway, against decline of renal function in
patients with chronic kidney disease and type 2 diabetes.
Therefore, this might be an opening line for novel therapeutic
targets and monitoring tools for metabolic traits and CVD.
Next, we assessed the clinical application of Prx4 for the
risk prediction of CVD. To do this, we used information from a
general 10-year risk of CVD based on the Framingham risk
score
28 and examined whether Prx4 might have incremental
predictive value above this risk score. We did not develop new
models, but chose an appropriate approach in prediction
research by using the information retained in the existing
prediction model.
19,30,31,49 Of note, there are usually missing
values for baseline data in an observational study. We had
<10% of data missing, and we used a single imputation and
predictive mean matching. Imputation for missing values will
increase the power and precision of a study and minimize the
risk of biased ﬁndings.
50 Finally, we used reclassiﬁcation
measures, which are more sensitive and more clinically
relevant than C-statistic alone.
18,19,49 For CVD, the addition of
Prx4 to the Framingham risk score marginally improved
prediction in terms of discrimination and reclassiﬁcation.
Overall, the addition of Prx4 correctly reclassiﬁed 2.7% of
participants for risk of CVD obtained by the Framingham risk
score. Further studies are warranted to conﬁrm our ﬁndings
for this oxidative stress biomarker in different settings
17 and
among individuals with other comorbidities such as diabetes.
There are some limitations to this study that should be
addressed. Our cohort predominantly comprised white
adults, and it is therefore unknown whether our ﬁndings
can be generalized to nonwhites. The PREVEND cohort was
enriched for microalbuminuria at baseline. However, a
weighted method was performed to compensate for this,
which did not affect the results. Moreover, we investigated
the association of only baseline and not serial circulating
levels of Prx4 with the future risk of outcomes of interest.
The extent of within-individual variation over time might
affect the statistical power of a study.
51,52 For example,
higher variation can lead to less power, and then the
estimated risk is attenuated using a single Prx4 measure-
ment. Although we accounted for confounding of traditional
cardiovascular risk factors, a potential for uncontrolled or
residual confounding would be plausible. Finally, we had no
data on other oxidative stress markers such as oxidized low-
density lipoprotein and homocysteine to compare their
predictive values with that of Prx4.
In conclusion, our results suggest that higher serum Prx4
levels are associated with most cardiovascular risk factors
including albuminuria and hs-CRP in a general-population
cohort study. Moreover, higher serum Prx4 levels were
associated with a signiﬁcantly higher risk of incident CVD
events or CVD mortality and all-cause mortality after adjust-
ment for traditional cardiovascular risk factors. Prx4 margin-
ally improves the 10-year risk prediction for CVD when added
to the Framingham risk score.
Acknowledgments
We thank L. T. W. de Jong-van den Berg and S. T. Visser from the
Department of Social Pharmacy, Pharmacoepidemiology and Phar-
macotherapy, Groningen University Institute for Drug Exploration,
University of Groningen, University Medical Center Groningen, for
providing the data on pharmacy-registered use of antidiabetic
medication.
Sources of Funding
This workwas supported bytheNetherlands Heart Foundation,
Dutch Diabetes Research Foundation, and Dutch Kidney
Foundation.Thisresearchwasperformedwithintheframework
of the Center for Translational Molecular Medicine (http://
www.ctmm.nl)andprojectPREDICCt(grant01C-104-07).None
of the study sponsors had a role in the study design; in data
collection, analysis, or interpretation; in writingthe report; or in
the decision to submit for publication.
Disclosures
Drs Struck and Schulte hold patent rights to the peroxire-
doxin 4 assay and are employees of BRAHMS GmbH, the
manufacturer of the peroxiredoxin 4 assay. The present study
was not ﬁnanced by BRAHMS GmbH. No other author has any
potential conﬂicts of interest relevant to this article.
DOI: 10.1161/JAHA.112.002956 Journal of the American Heart Association 10
Peroxiredoxin 4 and Cardiovascular Disease Abbasi et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
HReferences
1. BhattacharyyaT,NichollsSJ,TopolEJ,ZhangR,YangX,SchmittD,FuX,ShaoM,
Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship
of paraoxonase 1 (PON1) gene polymorphisms and functional activity with
systemicoxidativestressandcardiovascularrisk.JAMA.2008;299:1265–1276.
2. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between
circulating oxidized low-density lipoprotein and incidence of the metabolic
syndrome. JAMA. 2008;299:2287–2293.
3. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing.
Nature. 2000;408:239–247.
4. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K.
Endothelial function and oxidative stress in renovascular hypertension. N Engl J
Med. 2002;346:1954–1962.
5. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R. Oxidative stress and human
diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev
Clin Lab Sci. 2009;46:241–281.
6. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of
oxidative damage in human disease. Clin Chem. 2006;52:601–623.
7. Strobel NA, Fassett RG, Marsh SA, Coombes JS. Oxidative stress biomarkers
as predictors of cardiovascular disease. Int J Cardiol. 2011;147:191–201.
8. Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N. Peroxiredoxin IV is a
secretable protein with heparin-binding properties under reduced conditions.
J Biochem. 2000;127:493–501.
9. Schulte J, Struck J, Bergmann A, Köhrle J. Immunoluminometric assay for
quantiﬁcation of peroxiredoxin 4 in human serum. Clin Chim Acta.
2010;411:1258–1263.
10. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson
RT, Fujiwara Y, Orkin SH, Van Etten RA. Essential role for the peroxiredoxin
Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature.
2003;424:561–565.
11. Wood ZA, Schröder E, Robin Harris J, Poole LB. Structure, mechanism and
regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32–40.
12. Ding Y, Yamada S, Wang KY, Shimajiri S, Guo X, Tanimoto A, Murata Y, Kitajima
S, Watanabe T, Izumi H, Kohno K, Sasaguri Y. Overexpression of peroxiredoxin
4 protects against high-dose streptozotocin-induced diabetes by suppressing
oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal.
2010;13:1477–1490.
13. Wei Q, Jiang H, Xiao Z, Baker A, Young MR, Veenstra TD, Colburn NH.
Sulﬁredoxin–peroxiredoxin IV axis promotes human lung cancer progression
through modulation of speciﬁc phosphokinase signaling. Proc Natl Acad Sci
USA. 2011;108:7004–7009.
14. Schulte J, Struck J, Köhrle J, Müller B. Circulating levels of peroxiredoxin 4 as a
novel biomarker of oxidative stress in patients with sepsis. Shock.
2011;35:460–465.
15. Nickel CH, Ruedinger J, Misch F, Blume K, Maile S, Schulte J, Köhrle J,
Hartmann O, Giersdorf S, Bingisser R. Copeptin and peroxiredoxin-4 indepen-
dently predict mortality in patients with nonspeciﬁc complaints presenting to
the emergency department. Acad Emerg Med. 2011;18:851–859.
16. Shah SH, de Lemos JA. Biomarkers and cardiovascular disease: determining
causality and quantifying contribution to risk assessment. JAMA.
2009;302:92–93.
17. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go
AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM,
McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW; American
Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and
Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel
markers of cardiovascular risk: a scientiﬁc statement from the American Heart
Association. Circulation. 2009;119:2408–2416.
18. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassiﬁ-
cation improvement calculations to measure usefulness of new biomarkers.
Stat Med. 2011;30:11–21.
19. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors
of cardiovascular risk: the role of reclassiﬁcation measures. Ann Intern Med.
2009;150:795–802.
20. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE,
Gansevoort RT; PREVEND Study Group. Albuminuria assessed from ﬁrst-
morning-void urine samples versus 24-hour urine collections as a predictor
of cardiovascular morbidity and mortality. Am J Epidemiol. 2008;168:897–905.
21. Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL;
Prevention of Renal and Vascular End-stage Disease (PREVEND) Study Group.
Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301:
1790–1797.
22. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT; PREVEND
Study Group Prevention of REnal and Vascular ENT Stage Disease. Pharmacy
data in epidemiological studies: an easy to obtain and reliable tool.
Pharmacoepidemiol Drug Saf. 2002;11:379–384.
23. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO,
Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Plasma procalcitonin and
risk of type 2 diabetes in the general population. Diabetologia. 2011;54:2463–
2465.
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek
JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney
Disease Epidemiology Collaboration). A new equation to estimate glomerular
ﬁltration rate. Ann Intern Med. 2009;150:604–612.
25. Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO,
Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Plasma procalcitonin is
associated with obesity, insulin resistance, and the metabolic syndrome. J Clin
Endocrinol Metab. 2010;95:E26–E31.
26. Stricker BH, Herings RM. Plea for the retention of the Dutch National Medical
Registration (LMR) to provide reliable information regarding public health and
healthcare. Ned Tijdschr Geneeskd. 2006;150:1916–1917.
27. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ,
Gans RO, Janssen WM, Grobbee DE; Prevention of Renal and Vascular End
Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts
cardiovascular and noncardiovascular mortality in general population. Circu-
lation. 2002;106:1777–1782.
28. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM,
Kannel WB. General cardiovascular risk proﬁle for use in primary care: the
Framingham Heart Study. Circulation. 2008;117:743–753.
29. SteyerbergEW, Vickers AJ,Cook NR, GerdsT, GonenM,ObuchowskiN,Pencina
MJ, Kattan MW. Assessing the performance of prediction models: a framework
for traditional and novel measures. Epidemiology. 2010;21:128–138.
30. Janssen KJ, Moons KG, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating
methods improved the performance of a clinical prediction model in new
patients. J Clin Epidemiol. 2008;61:76–86.
31. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr.
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med.
2011;365:213–221.
32. Marshall A, Altman DG, Holder RL. Comparison of imputation methods for
handling missing covariate data when ﬁtting a Cox proportional hazards
model: a resampling study. BMC Med Res Methodol. 2010;10:112.
33. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood
pressure covariates in survival analysis. Stat Med. 1999;18:681–694.
34. Horstkotte J, Perisic T, Schneider M, Lange P, Schroeder M, Kiermayer C,
Hinkel R, Ziegler T, Mandal PK, David R, Schulz S, Schmitt S, Widder J,
Sinowatz F, Becker BF, Bauersachs J, Naebauer M, Franz WM, Jeremias I,
Brielmeier M, Zischka H, Conrad M, Kupatt C. Mitochondrial thioredoxin
reductase is essential for early postischemic myocardial protection. Circula-
tion. 2011;124:2892–2902.
35. Dreja T, Jovanovic Z, Rasche A, Kluge R, Herwig R, Tung YC, Joost HG, Yeo GS,
Al-Hasani H. Diet-induced gene expression of isolated pancreatic islets from a
polygenic mouse model of the metabolic syndrome. Diabetologia.
2010;53:309–320.
36. Xie X, Li S, Liu S, Lu Y, Shen P, Ji J. Proteomic analysis of mouse islets after
multiple low-dose streptozotocin injection. Biochim Biophys Acta. 2008;1784:
276–284.
37. Simula MP, Cannizzaro R, Canzonieri V, Pavan A, Maiero S, Toffoli G, De Re V.
PPAR signaling pathway and cancer-related proteins are involved in celiac
disease-associated tissue damage. Mol Med. 2010;16:199–209.
38. Chung JC, Oh MJ, Choi SH, Bae CD. Proteomic analysis to identify biomarker
proteins in pancreatic ductal adenocarcinoma. ANZ J Surg. 2008;78:245–251.
39. Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA,
Krieger M, Wagner DD. Peroxiredoxin1 prevents excessive endothelial
activation and early atherosclerosis. Circ Res. 2008;103:598–605.
40. Martinez-PinnaR,Ramos-MozoP,Madrigal-Matute J,Blanco-ColioLM,LopezJA,
CalvoE,CamafeitaE,LindholtJS,MeilhacO,DelboscS,MichelJB,deCenigaMV,
EgidoJ,Martin-VenturaJL.Identiﬁcationofperoxiredoxin-1asanovelbiomarker
ofabdominalaorticaneurysm.ArteriosclerThrombVascBiol.2011;31:935–943.
41. EmergingRisk Factors Collaboration, Wormser D, Kaptoge S, DiAngelantonio E,
WoodAM,Pennells L,ThompsonA,SarwarN,KizerJR,LawlorDA,Nordestgaard
BG, Ridker P,SalomaaV,Stevens J,Woodward M,Sattar N,CollinsR,Thompson
SG, Whitlock G, Danesh J. Separate and combined associations of body-mass
index and abdominal adiposity with cardiovascular disease: collaborative
analysis of 58 prospective studies. Lancet. 2011;377:1085–1095.
42. Schulte J. Peroxiredoxin 4: a multifunctional biomarker worthy of further
exploration. BMC Med. 2011;9:137.
43. JinDY,ChaeHZ,RheeSG,JeangKT.Regulatoryroleforanovelhumanthioredoxin
peroxidase in NF-kappaB activation. J Biol Chem. 1997;272:30952–30961.
DOI: 10.1161/JAHA.112.002956 Journal of the American Heart Association 11
Peroxiredoxin 4 and Cardiovascular Disease Abbasi et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
H44. Wong CM, Chun AC, Kok KH, Zhou Y, Fung PC, Kung HF, Jeang KT, Jin DY.
Characterization of human and mouse peroxiredoxin IV: evidence for inhibition
by Prx-IV of epidermal growth factor- and p53-induced reactive oxygen
species. Antioxid Redox Signal. 2000;2:507–518.
45. Giguère P, Turcotte ME, Hamelin E, Parent A, Brisson J, Laroche G, Labrecque
P, Dupuis G, Parent JL. Peroxiredoxin-4 interacts with and regulates the
thromboxane A(2) receptor. FEBS Lett. 2007;581:3863–3868.
46. Bertolotti M, Yim SH, Garcia-Manteiga JM, Masciarelli S, Kim YJ, Kang MH,
Iuchi Y, Fujii J, Vené R, Rubartelli A, Rhee SG, Sitia R. B- to plasma-cell terminal
differentiation entails oxidative stress and profound reshaping of the
antioxidant responses. Antioxid Redox Signal. 2010;13:1133–1144.
47. Münzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in
cardiovascular disease? Eur Heart J. 2010;31:2741–2748.
48. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz
S, Audhya P, Christ-Schmidt H, Wittes J; BEAM Study Investigators.
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl
J Med. 2011;365:327–336.
49. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new
biomarkers and predictive models for use in clinical practice: a clinician’s
guide. Arch Intern Med. 2008;168:2304–2310.
50. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing
values is superior to complete case analysis and the missing-indicator method
in multivariable diagnostic research: a clinical example. J Clin Epidemiol.
2006;59:1102–1109.
51. Koenig W, Sund M, Fröhlich M, Löwel H, Hutchinson WL, Pepys MB.
Reﬁnement of the association of serum C-reactive protein concentration and
coronary heart disease risk by correction for within-subject variation over
time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol.
2003;158:357–364.
52. Danesh J, Wheeler JG, Hirschﬁeld GM, Eda S, Eiriksdottir G, Rumley A, Lowe
GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers
of inﬂammation in the prediction of coronary heart disease. N Engl J Med.
2004;350:1387–1397.
DOI: 10.1161/JAHA.112.002956 Journal of the American Heart Association 12
Peroxiredoxin 4 and Cardiovascular Disease Abbasi et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
H